Cumberland Pharmaceuticals

Cumberland has a portfolio of FDA-approved branded prescription medicines for acute care settings. Its marketed products include treatments for acetaminophen poisoning, pain/fever management, constipation relief, H. pylori eradication therapy, hyponatremia treatment in hospitals, serious bacterial infections including MRSA and VAP/HAP. The company’s lead pipeline candidate ifetroban recently completed a successful Phase II study in cardiomyopathy associated with Duchenne muscular dystrophy and has received orphan drug designations[4][8]. Caldolor’s expanded labeling now includes infants as young as three months old[2][6]. Vibativ was recently approved in China.